<DOC>
	<DOCNO>NCT00279825</DOCNO>
	<brief_summary>The objective study compare pharmacokinetics pharmacodynamics IPX054 , carbidopa-levodopa immediate-release tablet , carbidopa-levodopa controlled-release tablet subject idiopathic Parkinson 's disease .</brief_summary>
	<brief_title>Comparison IPX054 , IR Carbidopa-Levodopa , CR Carbidopa-Levodopa Subjects With Parkinson 's Disease</brief_title>
	<detailed_description>IPX054 contain two different drug call levodopa carbidopa one tablet . - levodopa turn material call 'dopamine ' brain . The dopamine help improve symptom Parkinson 's disease . - carbidopa belongs group medicine call 'aromatic amino acid decarboxylase inhibitor ' . It help levodopa work effectively slow speed levodopa break body .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Diagnosed idiopathic Parkinson 's disease . Currently treat immediaterelease controlledrelease carbidopalevodopa require 200 mg levodopa per dose . Must experience `` wear OFF '' dose medication . Diagnosed atypical parkinsonism . Allergic nonresponsive previous carbidopalevodopa therapy . Active history narrowangle wideangle glaucoma . History seizure epilepsy , currently take anticonvulsant treatment seizure . Treatment neuroleptic agent , include atypical neuroleptic , within previous 12 month . Treatment dopaminergic blocking agent within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>